Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | RXRG | P48443 | 1/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241237 | 0.89 | LMNA (0.59) | LMNAHPGDRAB9AMAPTL3MBTL1 | |
| SCHEMBL16929834 | 0.89 | LMNA (0.59) | LMNAHPGDRAB9AMAPTL3MBTL1 | |
| SCHEMBL23226754 | 0.89 | FFAR4 (0.59) | LMNAHPGDRAB9AMAPTL3MBTL1 | |
| SCHEMBL3245222 | 0.88 | SMPD1 (0.67) | LMNAHPGDRAB9AMAPTL3MBTL1 | |
| SCHEMBL27703866 | 0.87 | FFAR4 (0.58) | HPGDRAB9AMAPTL3MBTL1FFAR4 | |
| SCHEMBL13440181 | 0.87 | FFAR4 (0.58) | HPGDRAB9AMAPTFFAR4RXRA | |
| SCHEMBL13440174 | 0.87 | RXRA (0.70) | FFAR4RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL20887673 | 0.86 | TDP1 (0.54) | LMNAHPGDRAB9AMAPTL3MBTL1 | |
| SCHEMBL2188210 | 0.86 | SMPD1 (0.76) | LMNAHPGDRAB9AMAPTRXRA | |
| SCHEMBL1782909 | 0.86 | HPGD (0.72) | LMNAHPGDRAB9AMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2020-07-02 | — | — | US | disclosed |
| EP-2794556-B1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | GLEASON JAMES L (CA) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 95/4885HPGD 561/4885RAB9A 1609/4885 |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK6, PCSK7 | LMNA 103/4885HPGD 552/4885RAB9A 1402/4885 |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 95/4885HPGD 561/4885RAB9A 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.